What is known about the long-term safety of cognitive enhancement peptides?

Cognitive peptides like Semax and Selank have not undergone large-scale FDA clinical trials, so their complete long-term safety profile remains incompletely characterized. Research indicates these peptides are generally well-tolerated with low toxicity risk since they are naturally metabolized by the body. Semax has decades of pharmaceutical use in Russia with an excellent tolerability record, though this does not constitute FDA approval. Anyone considering cognitive peptides should consult with a qualified healthcare provider and understand these compounds remain investigational in most countries.